{"blog": [], "keywords": [{"value": "Gilead Sciences Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Leukemia", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Europe", "name": "glocations", "rank": "3", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "4", "is_major": "Y"}, {"value": "European Medicines Agency", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "Roche Holding AG", "name": "organizations", "rank": "6", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/12/business/europe-investigates-safety-of-gilead-leukemia-drug.html", "document_type": "article", "byline": {"person": [], "original": "By REUTERS", "organization": "REUTERS"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "84", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "European regulators have started a review into the safety of Gilead Sciences\u2019 leukemia drug Zydelig over concerns about serious adverse events, including deaths.", "pub_date": "2016-03-12T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Europe Investigates Safety of Gilead Leukemia Drug", "main": "Europe Investigates Safety of Gilead Leukemia Drug", "content_kicker": "Business Briefing"}, "print_page": "2", "snippet": "European regulators have started a review into the safety of Gilead Sciences\u2019 leukemia drug Zydelig over concerns about serious adverse events, including deaths.", "_id": "56e360f638f0d81b768a68a3", "slideshow_credits": null, "abstract": "European regulators announce start of safety review of Gilead Sciences\u2019 leukemia drug Zydelig following rise in number of harmful events reports, including deaths, during three clinical trials."}